BARDA Selects Pharm-Olam to Support Clinical Trial Planning & Execution for up to 5 Years

BARDA selects Pharm-Olam to join its Clinical Studies Network. The IDIQ agreement is for a minimum of two years and a maximum of five years with a total ceiling value of $250 million. Pharm-Olam will provide CRO services for medical countermeasures (MCMs) development.